Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS Studies.

Samuel F HunterRany A AburashedRaed AlroughaniAndrew ChanDominique DiveSara EichauDaniel KantorHo Jin KimJan LyckeRichard A L MacdonellCarlo PozzilliThomas ScottBasil SharrackHeinz WiendlLuke ChungNadia DaizadehDarren P BakerPatrick Vermerschnull null

Published in: Neurology and therapy (2021)

CDI achievement at any point during the CARE-MS studies was associated with improved disability at year 9, highlighting the potential of alemtuzumab to change the multiple sclerosis course. Conversely, CDW at any point was associated with worsened disability at year 9.

Keyphrases

multiple sclerosis
healthcare
white matter
palliative care
quality improvement
pain management
case control
ms ms
type diabetes
risk assessment
metabolic syndrome
climate change
affordable care act
chronic pain
newly diagnosed
weight loss